Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

470 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm. The investigators propose to conduct a double blind, randomized, placebo controlled clinical trial of ergocalciferol supplementation to confirm safety and determine effects on Erythropoietin (EPO) dosing, active D dosing, and mineral metabolic parameters in hemodialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

NCT01263028

Chronic Kidney Disease Stages 3-5

TERMINATED NA

Ergocalciferol in Chronic Kidney Disease

NCT00411294

Chronic Kidney Disease

COMPLETED

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

NCT01312441

Vitamin D Deficiency Renal Failure Chronic Requiring Hemodialysis

TERMINATED PHASE4

Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease

NCT01835691

Chronic Kidney Disease

COMPLETED NA

Repletion of Ergothioneine in Patients With Kidney Failure

NCT06487546

Esrd

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ergocalciferol supplementation

Group Type OTHER

ergocalciferol supplementation

Intervention Type DIETARY_SUPPLEMENT

50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ergocalciferol supplementation

50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly

Intervention Type DIETARY_SUPPLEMENT

placebo

placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

vitamin D, D2 sugar pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients treated with thrice weekly in-center hemodialysis (HD) for more than 90 days.
2. Treated with EPO for at least 90 days. The mode of administration, intravenous (IV) or subcutaneous (SC), must remain the same for 90 days prior to enrollment.
3. The method by which EPO is prescribed (per DCI Corporate or local protocol or per physician on an individualized basis) must remain the same for at least 90 days prior to enrollment with respect to the ceiling for the total EPO dose administered per week, if a ceiling is used, and the level of hemoglobin (Hgb) at which EPO is discontinued (Hgb cutoff), if a Hgb cutoff is used.
4. The method by which IV Iron is prescribed (per DCI Corporate or local protocol or per physician on an individualized basis) must remain the same for at least 90 days prior to enrollment with respect to the serum ferritin and transferrin saturation (TSAT) targeted, if specific ferritin and TSAT targets are used

Exclusion Criteria

1. Patients with a serum calcium ≥10.5 mg/dL on at least one occasion in the past 30 days.
2. Patients with a serum phosphorus \>8.0 mg/dL on at least one occasion in the past 30 days.
3. Active infection defined by the use of IV antibiotic use within the past 30 days.
4. Current use of immunosuppressant medications other than low dose corticosteroids (prednisone \<10 mg per day or equivalent)
5. History of a hematological malignancy (e.g. multiple myeloma, leukemia).
6. Sickle cell disease (sickle cell trait is not an exclusion).
7. Myelodysplasia requiring 1 or more blood transfusions in the past 3 months.
8. Transfusion for any reason within the past 30 days.
9. Medical conditions that cause a reduction in the absorption of oral vitamin D including Crohn's disease, celiac sprue, cystic fibrosis and surgical removal of part or all of the stomach or intestine.
10. Medications that cause a reduction in the absorption of oral vitamin D including cholestyramine (Questran, others), colestipol (Colestid, others) and orlistat (Xenical, Alli).
11. Known allergy/adverse reaction to ergocalciferol.
12. Treated with ergocalciferol and/or cholecalciferol (except if part of a multi-vitamin) within the last 3 months.
13. Average Kt/V \< 1.3 on past three monthly labs. There must be at least 2 monthly Kt/V values in the past three months.
14. Skipped more than 3 dialysis treatments (excluding planned missed treatments) within the past 3 months for reasons other than hospitalization.
15. Life expectancy less than 6 months.
16. Kidney transplantation planned in the next 6 months.
17. Switch to peritoneal dialysis planned in the next 6 months.
18. Pregnant or planning to become pregnant within the next 6 months. A pre-menopausal woman must agree to use contraception for the duration of the study. If a woman has not had menses in over 12 months, consider this patient to be menopausal.
19. Unable or unwilling to give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No